ImmunityBio Inc (IBRX) ticks all the boxes for top investors with its surprise performance of -21.80% last month.

Shaun Noe

ImmunityBio Inc (NASDAQ: IBRX) kicked off on Tuesday, down -3.26% from the previous trading day, before settling in for the closing price of $2.15. Over the past 52 weeks, IBRX has traded in a range of $1.83-$5.43.

A company in the Healthcare sector has jumped its sales by 2.39% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 27.10%. With a float of $303.30 million, this company’s outstanding shares have now reached $984.97 million.

ImmunityBio Inc (IBRX) Insider and Institutional Ownership

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of ImmunityBio Inc is 69.21%, while institutional ownership is 14.61%.

ImmunityBio Inc (IBRX) Latest Financial update

In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.08 earnings per share (EPS), higher than consensus estimate (set at -0.13) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 27.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.07% during the next five years compared to 2.39% growth over the previous five years of trading.

ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators

Take a look at ImmunityBio Inc’s (IBRX) current performance indicators. Last quarter, stock had a quick ratio of 5.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.82.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.42, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.33 in one year’s time.

Technical Analysis of ImmunityBio Inc (IBRX)

Let’s dig in a bit further. During the last 5-days, its volume was 9.23 million. That was better than the volume of 8.36 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 52.87%.

During the past 100 days, ImmunityBio Inc’s (IBRX) raw stochastic average was set at 11.21%, which indicates a significant decrease from 44.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.12 in the past 14 days, which was lower than the 0.14 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $2.38, while its 200-day Moving Average is $2.64. However, in the short run, ImmunityBio Inc’s stock first resistance to watch stands at $2.16. Second resistance stands at $2.23. The third major resistance level sits at $2.29. If the price goes on to break the first support level at $2.03, it is likely to go to the next support level at $1.97. The third support level lies at $1.90 if the price breaches the second support level.

ImmunityBio Inc (NASDAQ: IBRX) Key Stats

The company with the Market Capitalisation of 2.05 billion has total of 984,965K Shares Outstanding. Its annual sales at the moment are 14,750 K in contrast with the sum of -413,560 K annual income. Company’s last quarter sales were recorded 32,060 K and last quarter income was -67,250 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.